Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy

Patient-derived tumour organoids (PDOs) have revolutionised our understanding of cancer biology and the applications of personalised therapies. These advancements are principally ascribed to the ability of PDOs to consistently recapitulate and maintain the genomic, proteomic and morphological charac...

Full description

Saved in:
Bibliographic Details
Published in:Acta biomaterialia 2022-07, Vol.146, p.23-36
Main Authors: Wu, Wence, Li, Xiaoyang, Yu, Shengji
Format: Article
Language:English
Subjects:
Biobank
Biology
Cancer
Cancer biology
Clinical trial
Customization
Humans
Neoplasms - drug therapy
Neoplasms - therapy
Organoids
Organoids - pathology
Patient-derived tumour organoids
Patients
Personalised therapy
Physical characteristics
Proteomics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patient-derived tumour organoids (PDOs) have revolutionised our understanding of cancer biology and the applications of personalised therapies. These advancements are principally ascribed to the ability of PDOs to consistently recapitulate and maintain the genomic, proteomic and morphological characteristics of parental tumours. Given these characteristics, PDOs (and their extended biobanks) are a representative preclinical model eminently suited to translate relevant scientific findings into personalized therapies rapidly. Here, we summarise recent advancements in PDOs from the perspective of cancer biology and clinical applications, focusing on the current challenges and opportunities of reconstructing and standardising more sophisticated PDO models. Patient-derived tumour organoids (PDOs), three-dimensional (3D) self-assembled organotypic structures, have revolutionised our understanding of cancer biology and the applications of personalised therapies. These advancements are principally ascribed to the ability of PDOs to consistently recapitulate and maintain the genomic, proteomic and morphological characteristics of parental tumours. Given these characteristics, PDOs (and their extended biobanks) are a representative preclinical model eminently suited to translate relevant scientific findings into personalized therapies rapidly. [Display omitted]
ISSN:1742-7061
1878-7568
DOI:10.1016/j.actbio.2022.04.050